Last edition
News about
NAYA Therapeutics Partners with Atley Solutions on Astatine-211 Radio Pharmaceuticals
NAYA Therapeutics will leverage Atley’s clinical manufacturing network and establish additional GMP sites using the Atley C100 for the final clinical-dose manufacturing of 211 At Targeted Alpha Therapies.
Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis
Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.
Julius Clinical Strengthens CNS and Cardiometabolic Expertise, Adds Operations in Spain and Germany
Julius Clinical has reported strong Q2 2025 growth in CNS and Cardiometabolic bookings, driven by its merger with Peachtree BioResearch Solutions and expanded operations in Spain and Germany.
Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671
Onco3R Therapeutics is expected to start enrolling subjects for the first-in-human trial of SIK3 inhibitor O3R-5671 over the coming weeks, with dosing of the first subject anticipated later in September.
Cayman Chemical, Curapath Join Forces to Expand Access to PEG-Free Shielding Lipids for LNPs
Cayman Chemical and Curapath have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies.
Johnson & Johnson has launched two new products for astigmatic patients in Europe and the Middle East, including the first daily disposable multifocal contact lens for astigmatic presbyopes.
Roche Deploys Contivue Manufacturing Platform with CE Mark for nAMD Continuous Drug Delivery
Roche has received CE marking in the European Union for Contivue, its innovative Port Delivery Platform for administering Susvimo in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
The Indian government has issued a clarification under the Uniform Code for Pharmaceutical Marketing Practices, mandating that drug and medical device manufacturers must value free promotional samples using the same price charged to the stockist or immediate customer.
Alkem's Enzene Invests USD 70 Million in US Manufacturing Expansion
Enzene Biosciences, the biotechnology subsidiary of Alkem Laboratories—one of India’s leading pharmaceutical companies—has established its first US-based manufacturing facility with a USD 70 million investment.
India to Reform New Drugs and Clinical Trials Rules, Halve Processing Time for Test Licences
By amending the New Drugs and Clinical Trials (NDCT) Rules, 2019, the Indian government aims to simplify the requirements and procedures for obtaining test licences and for submitting applications related to Bioavailability/Bioequivalence (BA/BE) studies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy